These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 30134961)

  • 1. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.
    Vitale F; Giliberto L; Ruiz S; Steslow K; Marambaud P; d'Abramo C
    Acta Neuropathol Commun; 2018 Aug; 6(1):82. PubMed ID: 30134961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.
    Nisbet RM; Van der Jeugd A; Leinenga G; Evans HT; Janowicz PW; Götz J
    Brain; 2017 May; 140(5):1220-1230. PubMed ID: 28379300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
    Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
    J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.
    d'Abramo C; Acker CM; Jimenez H; Davies P
    PLoS One; 2015; 10(8):e0135774. PubMed ID: 26270821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
    Boutajangout A; Ingadottir J; Davies P; Sigurdsson EM
    J Neurochem; 2011 Aug; 118(4):658-67. PubMed ID: 21644996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models.
    Vitale F; Ortolan J; Volpe BT; Marambaud P; Giliberto L; d'Abramo C
    Acta Neuropathol Commun; 2020 Aug; 8(1):126. PubMed ID: 32762731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.
    Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R
    J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
    Asuni AA; Boutajangout A; Quartermain D; Sigurdsson EM
    J Neurosci; 2007 Aug; 27(34):9115-29. PubMed ID: 17715348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
    Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
    J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration.
    Forman MS; Lal D; Zhang B; Dabir DV; Swanson E; Lee VM; Trojanowski JQ
    J Neurosci; 2005 Apr; 25(14):3539-50. PubMed ID: 15814784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting tauopathy with engineered tau-degrading intrabodies.
    Gallardo G; Wong CH; Ricardez SM; Mann CN; Lin KH; Leyns CEG; Jiang H; Holtzman DM
    Mol Neurodegener; 2019 Oct; 14(1):38. PubMed ID: 31640765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.
    Ward SM; Himmelstein DS; Ren Y; Fu Y; Yu XW; Roberts K; Binder LI; Sahara N
    Neurobiol Dis; 2014 Jul; 67():37-48. PubMed ID: 24631720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.
    Selenica ML; Davtyan H; Housley SB; Blair LJ; Gillies A; Nordhues BA; Zhang B; Liu J; Gestwicki JE; Lee DC; Gordon MN; Morgan D; Dickey CA
    J Neuroinflammation; 2014 Sep; 11():152. PubMed ID: 25183004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity.
    d'Abramo C; Acker CM; Jimenez HT; Davies P
    PLoS One; 2013; 8(4):e62402. PubMed ID: 23638068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology.
    Leroy K; Ando K; Héraud C; Yilmaz Z; Authelet M; Boeynaems JM; Buée L; De Decker R; Brion JP
    J Alzheimers Dis; 2010; 19(2):705-19. PubMed ID: 20110614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice.
    Britschgi M; Takeda-Uchimura Y; Rockenstein E; Johns H; Masliah E; Wyss-Coray T
    J Neuroinflammation; 2012 Sep; 9():220. PubMed ID: 22989354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau antibody isotype induces differential effects following passive immunisation of tau transgenic mice.
    Bajracharya R; Brici D; Bodea LG; Janowicz PW; Götz J; Nisbet RM
    Acta Neuropathol Commun; 2021 Mar; 9(1):42. PubMed ID: 33712083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.
    Boimel M; Grigoriadis N; Lourbopoulos A; Haber E; Abramsky O; Rosenmann H
    Exp Neurol; 2010 Aug; 224(2):472-85. PubMed ID: 20546729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody.
    Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M
    Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
    Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
    J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.